Coping with cancer

A Cuban-American biotechnology company is employing to prove the effectiveness of Cuban anti-lung treatment, in anticipation of its possible use on American patients, as part of a remarkable collaboration in medical research between two long-time hostile countries.
This treatment, still in the experimental phase, called Semaphax-EGF, has caused an uproar in recent months, even before the announcement of this unprecedented agreement.
Several websites promote the superconductors attributed to this treatment, but the reality seems more complex. The researcher at the Havana Molecular Immunology Center, Orestes Santos, prefers to talk about "active immunity" working on the EGF protein.
"Lung cancer tumors need the EGF protein to grow and multiply, and our center has developed a product that produces antibodies to counter this protein," said the researcher at AFP.
"This is an extra weapon in the fight against cancer that can be used alongside other therapeutic weapons such as chemotherapy," Santos said.